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Targeting Secondary Protein Complexes in Drug Discovery: 
Studying the Druggability and Chemical Biology of the 
HSP70/BAG1 Complex 
Lindsay E. Evans,
a
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a
 and Matthew D. Cheeseman
a
Proteins typically carry out their biological functions as multi-
protein complexes, which can significantly affect the affinity of 
small-molecule inhibitors. HSP70 is an important target in 
oncology, so to study its chemical biology and the drug discovery 
potential of the HSP70/BAG1 complex, we designed a high-affinity 
non-nucleotide fluorescence polarisation probe. 
The search for new therapeutics used to rely on cell-based 
assays to discover bioactive small-molecule hit matter.
1
 
Following the advent of readily available recombinant 
proteins, this phenotypic paradigm was largely replaced by 
high-throughput screening against individual protein targets.
2
 
Although the molecularly-targeted approach has delivered 
considerable success against certain protein families,
3
 
particularly kinases,
4
 others have proven less amenable. This 
has led to many proteins being considered undruggable, often 
after a failure to translate biochemical potency to cellular 
activity.
5
 Proteins carry out their functions through the 
formation of multi-protein complexes;
6
 however, assays using 
recombinant proteins generally aim for simplicity in their 
design, measuring ligand affinity only for individual proteins. 
The opportunity to compare the druggability of small-molecule 
binding sites of primary versus secondary protein complexes is 
then lost and optimisation against an isolated target could 
have limited biological relevance, especially for proteins with a 
high degree of conformational flexibility.
7
 
 The 70 kDa heat shock protein family (HSP70) are 
molecular chaperones responsible for maintaining cell 
homeostasis
8
 and as such have become an important and 
popular target in oncology.
9
 The complexity of their catalytic 
cycle has been well studied
10
 but despite the research efforts 
of many groups, no drug targeting the HSP70 family and few 
good chemical tools to investigate their cellular function have 
been discovered.
11
 
 Our analysis of the proposed HSP70 catalytic cycle 
suggested that the protein rarely, if ever, is not in complex 
with other co-chaperones.
10
 HSP70 carries out its function in 
an ATP-dependent manner;
10
 the co-chaperone nucleotide-
exchange factor (NEF) BAG family molecular chaperone 
regulator 1 (BAG1) promotes the release of the tight-binding 
hydrolysis product, ADP/Pi, allowing ATP to rebind and agonise 
the catalytic cycle.
12
 Owing to the challenges of targeting 
HSP70, combined with our broad knowledge of its molecular 
mechanism of action (MOA) and protein binding partners, we 
decided to use HSP70 to explore strategies for targeting 
secondary protein complexes in drug discovery. 
 The nucleotide-binding domain (NBD) of the HSP70 
constitutively active homologue, HSC70, in complex with 
truncated BAG1 (residues 222-334, tr-BAG1)
11
 has been 
extensively studied using crystallography, allowing accurate 
comparison with primary HSP70-NBD structures (Figure 1).
11
 
According to these data, HSP70-NBD binds small-molecules in 
three distinct protein conformations. The ATP-bound HSC70-
NBD/tr-BAG1 ternary structure (Figure 1, grey PDB: 3FZF)
11
 
demonstrates the most open conformation of the binding 
cleft. In contrast, the secondary HSP72-NBD structure forms a 
closed conformation when ADP/Pi (Figure 1, blue, PDB: 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Cartoon overlay of the open HSC70-NBD/BAG1 ATP-bound complex 
(HSC70-NBD light grey, tr-BAG1 dark grey, ATP light grey. PDB: 3FZF) with the 
closed HSP72-NBD ADP/Pi-bound complex (HSP72-NBD light blue, ADP light blue 
PDB: 3ATU). Blue=nitrogen, red=oxygen, orange=phosphorus, hydrogens, 
solvent and protein residues omitted for clarity. For a description of key 
nucleotide interactions see the supplementary information. 
COMMUNICATION Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
3ATU)
13
 or certain small molecule inhibitors are bound.
14
 The 
majority of ligands observed by crystallography appear to bind 
an intermediate HSP70-NBD conformation (Figure 2, PDB: 
4IO8)
15
 and no examples of the open conformation have been 
observed in the absence of tr-BAG1. These structures suggest 
that BAG1 has a large and significant effect on the 
conformation of the adenine-binding pocket, so should also 
strongly affect the affinity of both nucleotide and non-
nucleotide ligands that bind at this site.
16
 However, some 
experimental evidence suggests that the ability of BAG1 to 
agonise nucleotide-exchange is actually through disruption of 
the phosphate-binding pocket of the NBD.
17
 To confirm which 
BAG1 nucleotide-exchange agonism MOA was correct and to 
assess whether the secondary HSP70/BAG1 complex 
represented a more druggable target for screening than the 
primary HSP70 protein, we hypothesised that an adenine-
derived probe could be designed to examine the effect of 
BAG1 on ATP-competitive small-molecule affinity. 
 Fluorescence polarisation (FP) is a versatile assay format, 
which we believed could be exploited for this study.
18
 The 
assay design required an FP-probe that could bind to both the 
primary HSP70 protein and the secondary HSP70/BAG1 
complex, with high affinity and via a binding mode distinct 
from the nucleotide ligands. The well validated 8-N-
benzyladenosine HSP70 inhibitors were selected as a start-
point for FP-probe design, due to their high affinity for various 
HSP70 isoforms,
11,15
 although their affinity has only ever been 
determined in the absence of BAG1. 
 Through analysis of the co-crystal structure of the Ver-
155008 1
11
 bound to the stress-inducible isoform, heat shock 
70 kDa protein 1 (HSP72-NBD, Figure 2),
16
 we identified the 6-
amino position of adenine as being solvent exposed and 
suitable for linker and fluorophore attachment. To maximize 
the range of inhibitor potencies that can be resolved in an FP-
assay, a tight-binding fluorescent probe is essential.
19
 Bisaryl 
nucleoside 2, a tight-binding analogue of Ver-155008 1, has a 
reported affinity for HSP72-NBD of KD=60 nM by surface-
plasmon resonance analysis,
11
 so was selected as the basis for 
design of the FP-probe (Scheme 1). 
The published route to the bisaryl chemotype
11
 was clearly 
not be suitable, as key to any successful synthesis would be to 
introduce the fluorophore in the final step, owing to its 
instability and difficult purification. Therefore, we designed a 
route which maintained an electrophilic C6-chloroadenine 
substituent until the final steps. Starting from the 
commercially available 3’,4’-acetonide-protected 6-
chloroadenosine 3 (Scheme 1, Route A), anionic 5’-O-
benzylation gave nucleoside 4 in low to moderate yield, due to 
competing oligomer formation from attack of the anion on the 
C6-chloro position. Unfortunately, without the 6-amino 
substituent in place, 4 was apparently too electron-deficient to 
undergo bromination at the C8-position and failed to afford 5 
using standard conditions,
11
 returning a complex mixture of 
products. To increase the reactivity of the 6-chloroadenine 
moiety, we attempted to deprotonate the C8-carbon of 4 using 
LDA and trap the resulting anion with 
dibromotetrachloroethane (DBTCE), but again without success, 
as only starting material was recovered. To complete the 
synthesis of the FP-probe, it would prove necessary to change 
the ribose protecting groups from acetonide to 3’,4’-
tributyldimethylsilylethers (TBS) (Scheme 1, Route B). 
Following selective primary TBS-ether deprotection of the tris-
TBS-protected 6-chloroadenosine 6 with a 4:1:1 mixture of 
THF/TFA/H2O and anionic 5’-O-benzylation of the resulting 
alcohol, treatment of bis-O-TBS-6-chloroadenosine 7 with LDA 
and DBTCE, now gave 8-bromoadenosine 8 in 92% yield. We 
speculated that the success of this transformation was due to 
a change in the adenosine conformation caused by the 
protecting group swap. The aminoquinoline group was then 
added via SNAr, with excellent (>10:1) selectivity for C8- over 
C6-substitution, followed by deprotection of the O-TBS-groups 
to give the key FP-probe precursor, 6-chloroadenosine 
derivative 9, in 77% yield. Finally, addition of the diamine 
linker and N-Boc-deprotection was followed by fluorescein-
labelling of the primary amine with 5-FAM-NHS-ester to afford 
the desired FP-probe 10 in 8 steps and 5% overall yield. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1 Synthesis of bisaryl FP-probes. 
 
 
 
 
 
 
 
 
Fig. 2 Ver-155008 1 bound to HSP72-NBD in an intermediate conformation but in 
the same pocket at the nucleotide ligands (PDB: 4IO8), the N6-adenine group is 
clearly solvent exposed at the front of the pocket (picture adapted from a ligand 
interaction analysis using MOE 2014.09). Only key residues are shown, solvent 
and hydrogens are omitted for clarity. Blue=nitrogen, red=oxygen, 
green=chlorine. 
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 The first bisaryl FP-probe 10 we designed used a standard 
fluorescein fluorophore but displayed an unusually high 
degree of background polarisation in the absence of protein, 
giving a small assay window (~30 mP, Figure 3A). As a result, 
the assay was not statistically robust, so could not be used in 
competition experiments (Z’=0.36).
11,20,21
 We hypothesised 
that the high lipophilicity of 10 (clogP=6.9) was causing the 
small binding window, either due to aggregation, even at very 
low concentrations, or its large hydrate volume.
22
 Because the 
lipophilicity of the specific-ligand portion of the probe was 
fixed by the need for high affinity to the HSP70 target, we 
focused on changes to the solvent exposed fluorophore. ATTO-
488, a green-shifted fluorophore that contains two sulfonic 
acid groups, was selected as an alternative to fluorescein (see 
supplementary information), as this reduced the cLogP of the 
bisaryl probe 11 to -3.9. The binding window of ATTO-488 
bisaryl FP-probe 11 measured at a fixed and apparently 
saturating concentration of HSP72 (5 M), was now greater 
than 150 mP (Z’=0.63, Figure 3A and Figure S1). 
 To determine the binding affinity of bisaryl FP-probe 11 for 
HSP72, it was titrated against increasing concentrations of the 
protein, using a fixed concentration (10 nM) of the FP-probe. 
Commercially available ATP-ATTO-488 was originally used as a 
positive control (Figure 3B); however, it became clear that the 
affinity of of the nucleotide-derived probe was time-
dependent (Figure S2), initially returning an apparent KD of 
only ~1.5 M and plateauing at 290 nM (pKD=6.54±0.03, n=4) 
after 6 hours incubation. We speculated that this decrease in 
apparent KD was due to the slow hydrolysis of the ATP-probe 
to ADP-ATTO-488 + Pi. Although HSP72 has low intrinsic 
ATPase activity,
8
 the high enzyme concentration could catalyse 
hydrolysis over the time-frame of the assay, with the initial KD 
values reflective of the known modest affinity of ATP for 
HSP70, whilst the final KD value was consistent with the higher 
affinity ADP ligand.
14
 The bisaryl-ATTO-488 FP-probe 11 
displayed no apparent time-dependency in its affinity and 
subsequent analysis of its binding isotherms to HSP72 revealed 
a KD value of 194 nM (pKD=6.72±0.04, n=4, Figure 3B). No 
detergent effects were displayed by either FP-probe (Figure 
S3) and binding specificity for 11 was confirmed by 
competition with the parent bisaryladenosine inhibitor 2, 
displaying an IC50=137 nM (pIC50=6.87±0.05, n=3) at the 
apparent tight-binding limit for the assay (Figure S4).
20
 
Truncated HSP72-NBD (residues 3 to 382) and HSC70-NBD 
(residues 4 to 381), often used in crystallography experiments 
and in the previous affinity assessments with this 
chemotype,
11,15
 displayed higher affinity for the FP-probe 11 
than full-length HSP72 (Figure S5). 
 To investigate the role of the secondary protein complex in 
the binding affinity of ligands for HSP70, we needed to confirm 
the formation of the protein-protein interaction between 
HSP72 and BAG1 in solution under the assay conditions. 
Because BAG1 is a known NEF, we hypothesized that it would 
reduce the affinity of the ATP-ATTO-488 FP-probe when the 
secondary complex forms, leading to a reduction in observed 
polarisation. BAG1 was titrated against a fixed concentration 
of HSP72 (195 nM) and ATP-ATTO-488 (10 nM), concentrations 
were selected to give a 50% bound fraction of the FP-probe in 
the assay.
20
 The increasing concentration of BAG1 clearly 
reduced the affinity of the ATP-ATTO-488 FP-probe in a dose-
dependent and saturatable manner, consistent with the 
formation of the secondary HSP72/BAG1 protein complex, and 
reaching a plateau at 680 nM BAG1 and 50 mP (Figure 3C). 
These data are consistent with previous studies, suggesting 
that the secondary HSP70/BAG1 complex displays much lower 
affinity for nucleotide ligands but the binding of BAG1 and the 
nucleotide is not necessarily mutually exclusive.
10,17,18
 
 To assess what effect the secondary HSP72/BAG1 complex 
had on the apparent affinity of the non-nucleotide bisaryl-
ATTO-488 FP-probe 11, we carried out a similar BAG1 study. In 
 
 
 
 
 
 
 
 
 
Fig. 3 HSP72 fluorescence polarisation assays. All points are tested in triplicate and are represented as the arithmetic mean±SEM. All graphs were prepared and 
analysed using Graphpad Prism 7.01. A: Polarization values (mP) for 2–63 nM bisaryl-ATTO-488 FP-probe 11 (blue) and 8-125 nM bisaryl-FAM 10 (red) in the presence 
() and absence () of 5.0 μM HSP72, ↔ represents the maximum potential assay window. B: Representative binding isotherms for bisaryl-ATTO-488 FP-probe 11 
(blue) and ATP-ATTO-488 (red) with 20 nM to 10 μM HSP72 fitted to a one-site specific binding model. C: Displacement curve for ATP-ATTO-488 binding to HSP72 in 
the presence of 10 nM to 5.5 µM BAG1, isolated BAG1 displayed no measurable affinity for ATP-ATTO-488 or bisaryl-ATTO-488 11 see supplementary information. D: 
Affinity of bisaryl-ATTO-488 11 for HSP72 is maintained in the presence of a saturating concentration of BAG1 (1.0 M), whilst the ATP-ATTO-488 probe is clearly 
reduced. 
Table 1 Displacement of bisaryl-ATTO-488 11 FP-probe from the primary HSP72 
protein and secondary HSP72/BAG1 complex using nucleotide and non-
nucleotide ligands. 
Entry Compd 
IC50 (M)
a 
-BAG1 +BAG1b 
1 ADP 0.33 2.2 
2 ATP 0.65 >10 
3  2.0 2.0 
4  2.4 1.0 
a
Geometric mean of at least 3 independent experiments. 
b
700 nM BAG1 or the 
equivalent volume of the BAG1 buffer, was plated with 140 nM HSP72 (or 180 
nM for the plates without BAG1) to give a 50% bound fraction and were 
incubated for 16h prior to being read. 
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stark contrast to the ATP derived FP-probe, BAG1 treatment at 
an apparently saturating concentration (1.0 M) against the 
HSP72/bisaryl-ATTO-488 11 complex, resulted in no significant 
change in affinity of the probe (Figure 3D). No interaction 
between BAG1 and either ATP-ATTO-488 or bisaryl-ATTO-488 
11 was seen in the absence of HSP72 (Figure S6). To confirm 
that the binding of BAG1 to HSP72 was not mutually exclusive, 
we screened the nucleotides ADP and ATP in a competition 
assay with bisaryl-ATTO-488 11 and HSP72 at a 50% bound 
fraction, with and without a saturating concentration of BAG1 
(700 nM) (Figure S7). ADP (Table 1, Entry 1) displayed a 
significant 6.8-fold decrease in its affinity (IC50=2.2 M, 
pIC50=5.66±0.04, n=3) for the secondary complex compared to 
the primary HSP72 protein, with ATP (Table 1, Entry 2) 
displaying similar results. These data confirm the formation of 
the HSP72/BAG1/bisaryl-ATTO-488 11 ternary complex under 
the assay conditions and the weaker affinity of nucleotides for 
the secondary complex. The known non-nucleotide ligands, 
quinoline 12 (Table 1, Entry 3) and sangivamycin 13 (Table 1, 
Entry 4), displayed no significant change in their affinity for the 
HSP72/BAG1 complex compared to the primary protein, 
despite exploiting many of the same interactions in the 
adenine-binding pocket as the nucleotide ligands (see Figure 
S8).
15
 
 By developing an FP-probe derived from a high affinity 
non-nucleotide ligand, we were able to investigate the role of 
the NEF BAG1 in its secondary complex with HSP70. Our data 
suggests that BAG1 agonises nucleotide-exchange through 
conformational changes of the phosphate-binding pocket 
rather than the adenosine-binding pocket, as had been 
suggested by crystallography; while non-nucleotide ligands of 
HSP70 are apparently purely non-competitive with BAG1. This 
confirms the mechanistic hypothesis that phosphate 
dissociation is rate-determining in the NEF agonism of HSP70. 
Future crystallography efforts of the secondary complex 
should focus on utilizing full-length BAG1 to give greater 
insight into the molecular MOA, as tr-BAG1 cannot interact 
with the phosphate-binding pocket. Whether the new and 
unexplored phosphate-binding pocket conformation of the 
secondary HSP70/BAG1 complexes can be exploited to 
discover new hit-matter for inhibitors of HSP70 is currently 
unclear, as there are no known small-molecule non-nucleotide 
ligands that bind there. A screen using the bisaryl-ATTO-488 11 
FP-probe to confirm whether the HSP70/BAG1 complex can 
generate novel hit-matter is currently under investigation. 
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